Cambrian Biopharma has backed a round that will go toward further developing Vita’s lead candidate, VTA-110, for muscular dystrophy treatments.
US-based cell engineering developer Vita Therapeutics has secured $20m in a round led by ageing research group Cambrian Biopharma, Baltimore Business Journal has reported.
Spun out of Johns Hopkins University in 2019, Vita is working on stem cells that can contribute to muscle regeneration in patients suffering from muscular dystrophy – a type of genetic disease that causes muscle mass to weaken progressively.
Gabsang Lee, a neurology and neuroscience associate professor at Johns Hopkins, and Kathryn Wagner, director of the…
